OR WAIT null SECS
Cytiva and Pall reinforce recent expansion efforts with a $1.5-billion dollar investment in new manufacturing facilities.
On July 27, 2021, Cytiva and Pall, two subsidiaries of Danaher Corporation, announced that they will be making a $1.5 billion-investment toward expanding their manufacturing capacity and services.
The companies also released detailed plans on how the investment will be spent. The largest single investment, $600+ million, will go toward chromatography resins. Part of the $600+ million will specifically go toward establishing a new manufacturing site in the United States. The new facility is intended to complement the manufacturing capabilities of their Uppsala, Sweden, plant. No final location has been announced at this time.
Of the remaining sum, $400 million is going toward cell culture media; $300 million toward single-use technologies; and $200 million toward continuing expansion work in various countries.
This investment is the latest in a series of expansion moves made by the companies. In September 2020, Cytiva pledged $500 million over the course of five years on global manufacturing efforts. Since that announcement, Cytiva has already used the money to build a new manufacturing facility in Shrewsbury, Mass., and a new cleanroom in Westborough, Mass.
Additionally, since the September 2020 announcement Cytiva acquired companies such as Vanrx Pharmasystems, GoSilico, and Intermountain Life Sciences. In the same timeframe, Pall acquired Austar and Precision NanoSystems. Pall also announced plans to build a new plant in South Carolina and struck a manufacturing deal with Exothera.
Over the past year, Cytiva has hired 2000 new employees. With these plans in mind, the company is anticipating hiring 2000 more over the course of the next two years.